LGND
Ligand Pharmaceuticals Inc Health Care Pharmaceutical Preparations Russell 3000
$322.75Close
$6.4BMarket cap
$181.65 – $322.7552-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 91 · stronger than 91% of stocks over 12 months
- Near its high at its 52-week high
Cautions
- Earnings shrinking EPS −125% year on year
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 6.3%
price change
1mo
up 3.3%
price change
12-month return
up 73%
market up 11% ·
its own up 64%
F-score
—
— Not assessed
Altman Z
8.46
Low risk
P/E
51.3×
price / earnings
PEG
—
P/E / EPS growth
P/B
6.3×
price / book
Earnings yield
up 0.6%
EBIT / enterprise value
Cheaper than
28%
of the market · expensive
Revenue growth
up 60%
year on year
EPS growth
down 125%
latest quarter · -938 pts
Sales growth
down 32%
latest quarter · -66 pts
ROE
up 13%
return on equity
Free cash margin
up 18%
$48.9M FCF
D/E
0.44
long-term debt / equity
Net debt / EBITDA
3.6×
Interest cover
—EBIT / interest
Trade setup
ATR%
3.2%
$10.46 a day · 2×ATR $301.83
RS
91 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.5×
vs 50-day average
Up/down volume
1.16
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 3.5% over the year, from 19m to 20m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Profit not backed by cash Reported profit of $124.5M came with $49.4M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+3% vs market2 sessions after results
Financials
- Net 46%
- Free cash 18%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $163.6M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M |
| Operating income | $37.5M | $103.9M | $3.0M | $11.9M | -$22.6M | $41.0M |
| Net income | -$3.0M | $57.1M | -$33.4M | $52.2M | -$4.0M | $124.5M |
| Net margin | -2% | 24% | -17% | 40% | -2% | 46% |
| Earnings per share | -$0.18 | $3.31 | -$1.98 | $2.94 | -$0.22 | $6.13 |
| Free cash flow | $50.1M | $70.0M | $119.9M | $46.1M | $95.2M | $48.9M |
| Free cash margin | 31% | 29% | 61% | 35% | 57% | 18% |
| Cash | $47.6M | $19.5M | $45.0M | $23.0M | $72.3M | $174.9M |
| Long-term debt | — | — | — | — | $0 | $446.2M |
| Shareholders' equity | $709.5M | $821.2M | $597.5M | $700.9M | $830.4M | $1.0B |
| Shares outstanding | 16.08m | 16.77m | 16.95m | 17.56m | 19.11m | 19.77m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 30, 2026 | Quarterly ↗ | Sep 30, 2026 | 30d |
| Aug 7, 2026 | Quarterly ↗ | Jun 30, 2026 | 38d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Sep 24, 2026 | Regulation FD · Other events ↗ |
| Sep 22, 2026 | Regulation FD ↗ |
| Aug 6, 2026 | Results ↗ |
| Jul 14, 2026 | Material agreement · Acquisition or disposal · New obligation · Regulation FD ↗ |
| Jun 25, 2026 | Material agreement · New obligation · Unregistered share sale · Other events ↗ |
| Jun 22, 2026 | Material agreement · Other events ↗ |
| Jun 9, 2026 | Director or officer change · Shareholder vote ↗ |
| May 18, 2026 | Material agreement ↗ |
| May 7, 2026 | Results ↗ |
| Apr 30, 2026 | Agreement ended ↗ |
| Apr 27, 2026 | Material agreement · Other events ↗ |